United States: Guest Post - The FDA's Two-Day Meeting On Manufacturer Off-Label Communications

Last Updated: November 17 2016
Article by James Beck

Today’s guest post is by Liz Minerd, a Reed Smith associate, who closely followed the online feed of the recent FDA meeting that the Agency called to discuss what changes would be appropriate in its off-label promotion restrictions – although the official agenda steered away from both the terms “off-label” and “promotion”. What follows is her summary of two days of testimony from over 60 speakers, some of whom thought that it was crazy that any damn fool can say whatever s/he wants about off-label uses, except for manufacturers, who can’t even tell the truth although knowing the most about them due to ongoing pharmacovigilance obligations, and other speakers who … do not.

As always, our guest poster deserves 100% of the credit (and any blame) for her post. We’re only the piano-players. Take it away Liz.

**********

Last Wednesday and Thursday (Nov. 9-10, 2016), the FDA conducted a public meeting on "Manufacturer Communications Regarding Unapproved Uses of Approved or Cleared Medical Products.” The FDA's notice of the meeting (available here) stated:

FDA is engaged in a comprehensive review of its regulations and policies governing firms’ communications about unapproved uses of approved/cleared medical products, and the input from this meeting will inform FDA’s policy development in this area.

What that means, stripped of regulatory jargon, is that the FDA public meeting involved potential updating of the FDA's decades-old prohibition on truthful promotion of off-label uses by regulated manufacturers.

Over the course of two days, some 60 speakers presented diverse viewpoints about the FDA's current position on off-label communications, with the first day predominantly consisting of those in favor of easing restrictions and the second day of those in favor maintaining or increasing those restrictions.

Speakers advocating for an easing of the restrictions on off-label communications included the main participants in our healthcare system: (1) drug and device manufacturers, (2) third-party payors, (3) physicians, and (4) patients. Also speaking on this side were free speech advocates, even though the FDA's notice (as the Blog pointed out at the time) did not mention the First Amendment. But even among these speakers, there were differences in opinion as to, (i) who should receive the off-label communications and (ii) how much evidence should underlie the communication.

First, these speakers generally agreed that a manufacturer should be allowed to have expanded off-label communications with payors so that the payors would have sufficient information to develop formularies. Both the manufacturers and the payors focused on delays in getting drugs added to formularies in a timely manner if they are not able to communicate regarding new drugs (or new indications for drugs) until after approval of labeling recognizing new uses. They also advocated for allowing payors to receive post-approval off-label information to allow payors to make value-based decisions on coverage.

In addition, many (but not all) of these speakers supported allowing more opportunities for off-label manufacturer communications with physicians. In particular, physicians treating patients who suffer from rare or pediatric diseases—where off-label use is often the standard of care, because no labeled uses exist—advocated for allowing robust off-label discussions provided that they are backed by scientific evidence. On the device side, both manufacturers and physicians advocated for easing restrictions on off-label communications, because physicians often need technical assistance to use/program devices and restrictions on off-label communications can deprive those physicians of such assistance for off-label uses, thereby resulting in patient harm.

Only a few speakers advocated for allowing direct to consumer off-label communications. Those who advocated this position focused on the trend in patients taking a more active role in learning about their own medical care and the difficulty of restricting the flow of information where patients are performing their own internet research.

Second, speakers advocating for an easing of restrictions generally agreed that off-label communications should be based on scientific evidence. But opinions varied widely on how much scientific evidence should be required—from requiring peer review to accepting anecdotal or real-world experience evidence. Many recognized that it is too restrictive to only permit dissemination of re-prints because many physicians do not have the time to read full articles. Several speakers suggested that disclaimers could be used to provide context and further information to allow physicians to assess the level of evidentiary support for off-label information.

Several speakers expressed frustration with the FDA because the FDA has repeatedly delayed issuing clear guidance in this area, and the FDA's notice for the meeting only fleetingly mentioned the constitutional concerns. These speakers questioned whether the FDA is looking at potential changes to regulations of off-label communications through the appropriate framework if it is not focused on the recent First Amendment jurisprudence: United States v. Caronia, 703 F.3d 149 (2d Cir. 2012), and Amarin Pharma, Inc. v. FDA, 119 F. Supp.3d 196 (S.D.N.Y. 2015), in particular, and Sorrell v. IMS Health Inc., 564 U.S. 552 (2011), and Thompson v. Western States Medical Center, 535 U.S. 357 (2002), more generally.

Speakers advocating for increased restrictions on manufacturer off-label communications often cited historical examples of harm that occurred from unregulated drugs prior to the enactment of the FDCA. These speakers included: (1) family members of patients harmed by off-label use, (2) plaintiff-side consumer advocacy groups, (3) similarly pro-plaintiff public health research groups/academics, and (4) a whistleblower.

These speakers largely ignored the First Amendment implications of FDA regulation of off-label communications. Those who didn't ignore the First Amendment argued that the recent jurisprudence was wrongly decided, should be narrowly interpreted, or, in the case of Amarin, non-binding. Some also implied that manufacturers' claims of First Amendment protection should be discounted or ignored because those manufacturers restrict patient/plaintiffs' speech through confidentiality provisions included in settlement agreements.

Many of the speakers advocating for increased restrictions argued that manufacturers should not even be allowed to provide physicians with re-prints of articles. These speakers contended that the peer reviewed process is flawed, resulting in the publication of articles with little evidentiary basis. These speakers pointed to alleged "ghost-writing" and use of paid consultants by manufacturers to disseminate off-label information that, according to the speakers, already results in over-prescribing off-label uses. In their eyes, the FDA should be the only arbiter of whether information is backed by sufficient scientific evidence to justify permitted a manufacturer to disseminate it to physicians. These speakers argued that off-label uses backed by sufficient scientific evidence will not be kept a "secret" from physicians even if manufacturers are not permitted to disseminate information on these uses because physicians will learn of such uses from medical societies.

At the most extreme, some speakers advocated for the FDA to insert itself into the doctor-patient relationship (something that is illegal under 21 U.S.C. §396) and require physicians to obtain separate informed consent (potentially even provided by the FDA) before prescribing or using a drug or device off-label.

The FDA will be accepting written comments until January 9, 2017. Instructions for submitting written comments are available here.

This article is presented for informational purposes only and is not intended to constitute legal advice.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
James Beck
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.